top of page
Medvin icon
Medvin Clinical Research

Call Toll Free:
 1 (855) MEDVIN-1

  • Instagram
  • Facebook
  • LinkedIn
Scleroderma or Systemic Sclerosis.png

Scleroderma or Systemic Sclerosis

About this study... 48 week study plus possible extension study

Scleroderma or Systemic Sclerosis.png

Scleroderma or Systemic Sclerosis

About this study... 48 week study plus possible extension study

Trial Details

participating criteria.png

Participation Criteria

  • Must show evidence of active disease within 2 years

  • Worsening of skin thickening

  • Must be on a stable dose of concomitant treatment for SSC

locations.png

Participating Locations

  • Apple Valley

  • Riverside

  • Menifee

  • Covina

  • Whittier

  • Tujunga

compensation.png

  • Earn up to $1,000 for 13 visits in a year

Compensation

medications.png

  • New Investigational drug with Novel pathway to treat the disease

Medications

durations.png

  • 1 year study (13 office visits) followed by possibly an Open label extension study with no placebo

Durations

Do you have a confirmed diagnosis of Scleroderma or Systemic Sclerosis?
Have you previously been exposed to any biologics (Injections or Infusion medications)?
Do you have a history of any malignancy in the past 5 years?
Do you have a confirmed diagnosis of Scleroderma or Systemic Sclerosis?
Have you previously been exposed to any biologics (Injections or Infusion medications)?
Do you have a history of any malignancy in the past 5 years?
participating criteria.png

Participation  Criteria

  • Must show evidence of active disease within 2 years

  • Worsening of skin thickening

  • Must be on a stable dose of concomitant treatment for SSC

locations.png

Participating Locations

  • Apple Valley

  • Riverside

  • Menifee

  • Covina

  • Whittier

  • Tujunga

compensation.png

  • Earn up to $1,000 for 13 visits in a year

Compensation

medications.png

  • New Investigational drug with Novel pathway to treat the disease

Medications

durations.png

  • 1 year study (13 office visits) followed by possibly an Open label extension study with no placebo

Durations

Trial Details